PMID- 34417867
OWN - NLM
STAT- MEDLINE
DCOM- 20220228
LR  - 20220531
IS  - 1436-2813 (Electronic)
IS  - 0941-1291 (Linking)
VI  - 52
IP  - 3
DP  - 2022 Mar
TI  - Retrospective evaluation of the effect of Ninjin'yoeito in hepatocellular 
      carcinoma patients treated with lenvatinib.
PG  - 441-448
LID - 10.1007/s00595-021-02358-7 [doi]
AB  - PURPOSES: Lenvatinib (LEN) is a molecular-target drug, used for unresectable 
      hepatocellular carcinoma (HCC). It is associated with adverse events (AEs), 
      including hypertension, proteinuria, fatigue, and anorexia, which may force dose 
      reduction or discontinuation. Ninjin'yoeito (NYT) is a Chinese-Japanese herbal 
      compound that can effectively treat fatigue and anorexia, and which has been used 
      for chronic liver diseases. NYT reduces AEs and improves the liver function in 
      patients treated with sorafenib but its effect on LEN is unclear. METHODS: The 
      present study included 46 patients (male, n = 32; female, n = 14) who received 
      LEN for HCC at our hospital. Their median age was 70 years (range 36-88 years), 
      and their median body weight was 61.5 kg (range 38.4-97.0 kg). Patients were 
      divided into two groups, depending on whether they received NYT medication. Their 
      AEs and liver function were examined one month after starting LEN. RESULTS: The 
      NYT group suffered less fatigue (63.6% vs. 11.4%, P = 0.0014) and showed elevated 
      aspartate aminotransferase levels (45.5% vs. 14.3%, P = 0.0433) in comparison to 
      the non-NYT group. The non-NYT group also showed a significantly exacerbated 
      albumin-bilirubin (ALBI) grade (P = 0.0342) and ALBI score (average 
      change: + 0.232, P = 0.0001) at 1 month in comparison to baseline. CONCLUSION: 
      NYT apparently suppressed LEN-induced fatigue and helped maintain liver function 
      in patients with HCC.
CI  - (c) 2021. Springer Nature Singapore Pte Ltd.
FAU - Toshida, Katsuya
AU  - Toshida K
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Itoh, Shinji
AU  - Itoh S
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan. itoshin@surg2.med.kyushu-u.ac.jp.
FAU - Yoshizumi, Tomoharu
AU  - Yoshizumi T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Shimagaki, Tomonari
AU  - Shimagaki T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Wang, Huanlin
AU  - Wang H
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Kurihara, Takeshi
AU  - Kurihara T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Toshima, Takeo
AU  - Toshima T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Nagao, Yoshihiro
AU  - Nagao Y
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Harada, Noboru
AU  - Harada N
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Hata, Kojiro
AU  - Hata K
AD  - Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashiku, 
      Fukuoka, 812-8582, Japan.
FAU - Makihara, Yoko
AU  - Makihara Y
AD  - Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashiku, 
      Fukuoka, 812-8582, Japan.
FAU - Watanabe, Hiroyuki
AU  - Watanabe H
AD  - Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashiku, 
      Fukuoka, 812-8582, Japan.
FAU - Mori, Masaki
AU  - Mori M
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
LA  - eng
GR  - he Ministry of Health, Labour and Welfare, Japan/N/JSPS KAKENHI/
PT  - Journal Article
DEP - 20210821
PL  - Japan
TA  - Surg Today
JT  - Surgery today
JID - 9204360
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - 0 (ninjin'yoeito)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Carcinoma, Hepatocellular/drug therapy/pathology
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Humans
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Phenylurea Compounds/*therapeutic use
MH  - Quinolines/*therapeutic use
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - Ninjin'yoeito
EDAT- 2021/08/22 06:00
MHDA- 2022/03/01 06:00
CRDT- 2021/08/21 12:10
PHST- 2021/02/26 00:00 [received]
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/08/22 06:00 [pubmed]
PHST- 2022/03/01 06:00 [medline]
PHST- 2021/08/21 12:10 [entrez]
AID - 10.1007/s00595-021-02358-7 [pii]
AID - 10.1007/s00595-021-02358-7 [doi]
PST - ppublish
SO  - Surg Today. 2022 Mar;52(3):441-448. doi: 10.1007/s00595-021-02358-7. Epub 2021 
      Aug 21.